Richard S. Geary - Feb 2, 2024 Form 4/A - Amendment Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP, Chief Development Officer
Signature: Patrick R. O'Neil, attorney-in-fact For: Richard S. Geary
Stock symbol: IONS
Transactions as of: Feb 2, 2024
Transactions value $: -$99,836
Form type: 4/A - Amendment
Date filed: 9/4/2024, 09:33 PM
Date Of Original Report: Feb 2, 2024
Previous filing: Feb 2, 2024
Next filing: Mar 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IONS	Common Stock	Sale	-$99.8K	-2K	-2.23%	$50.04	87.3K	Feb 2, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The original Form 4 filed on February 2, 2024 reported 1,961 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Geary.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.80 to $50.30 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Content

The original Form 4 filed on February 2, 2024 reported 1,961 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Geary.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.80 to $50.30 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.